Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June $30,2025.$

Sunland Pharmaceutical Industries Selected Balance Sheet Information June $30,2025$

Long$-$term debt

Notes payable, $11\%$

$8\%$ convertible bonds payable

$11\%$ bonds payable

Total long$-$term debt

Shareholders' equity

Preferred stock, $6\%$ cumulative, $$50$ par value, $105,000$ shares authorized, $26,250$ shares issued and outstanding $\text{'}$ $$1,312,500$

Common stock, $$1$ par, $9,800,000$ shares authorized, $980,000$ shares issued and outstanding

$980,000$